Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-randomized Prospective Phase II Study of Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

NCT06120972 is registered in ClinicalTrials.gov with Alexander B Olawaiye, MD as lead sponsor.

NCT NCT06120972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06120972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-randomized Prospective Phase II Study of Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
Lead sponsor
Alexander B Olawaiye, MD
Phase
Phase 2
Overall status
Withdrawn
Start date
January 17, 2024
Completion date
December 31, 2029
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer